Drug Trial Radar · NCT05331183
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
297
Actual
Start
Nov 23, 2022
Primary completion
Apr 6, 2027
Study completion Apr 6, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic fibrosis (CF) with at least 1 non-F508del ELX/TEZ/IVA-responsive CF transmembrane conductance regulator (CFTR) gene mutation.
Conditions
- Cystic Fibrosis
Interventions
ELX/TEZ/IVADrug
Fixed-dose combination (FDC) tablets for oral administration.
IVADrug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 196
Locations
81 sites in 15 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck - Heilstättenschule Universitätsklinik
Innsbruck, Austria
CUB Hôpital Erasme
Brussels, Belgium
UZ Brussel - Campus Jette
Brussels, Belgium
Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Universite Catholique de Louvain - Pulmonology
Woluwe-Saint-Lambert, Belgium
Stollery Children's Hospital
Edmonton, Canada
Le Centre de recherche du CHUM (CRCHUM)
Montreal, Canada
McGill University Health Centre, Glen Site, Montreal Children's Hospital
Montreal, Canada
Hospital for Sick Children - Pulmonology
Toronto, Canada
British Columbia Children's Hospital
Vancouver, Canada
St. Paul's Hospital - Pulmonology
Vancouver, Canada
Klinika Detskych Infekcnich Nemoci
Brno, Czechia
Motol University Hospital
Prague, Czechia
Hopital Femme Mere-Enfant
Bron, France
Centre Hospitalier Intercommunal Creteil - Pulmonology
Créteil, France
Institut Cœur Poumon, CHU de Lille
Lille, France
Hopital Nord
Marseille, France
Hopital Arnaud de Villeneuve - Service de Pneumologie et Maladies Respiratoires
Montpellier, France
Hôpital Nord Laennec
Nantes, France
CHU de Nice - Hôpital Pasteur 2
Nice, France
Hopital Cochin - Pulmonology
Paris, France
Hopital Necker Enfants Malades - Pulmonology
Paris, France
Hopital Robert Debre - Pulmonology
Paris, France
Hôpital Lyon Sud - Pulmonology
Pierre-Bénite, France
Hôpital américain de Reims - Département de pédiatrie A
Reims, France
Hôpital Sud - Rennes
Rennes, France
Centre de Perharidy, Roscoff
Roscoff, France
Hopital Larrey
Toulouse, France
Hopital Bretonneau
Tours, France
Charité - Paediatric Pulmonology Department
Berlin, Germany
University Hospital Cologne (Koeln) - CF-Studienzentrum
Cologne, Germany
Ruhrlandklinik
Essen, Germany
Klinikum der Johann-Wolfgang-Goethe Universitaet - Pulmonology
Frankfurt, Germany
Justus-Liebig-Universität Gießen
Giessen, Germany
Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie
Halle, Germany
Medizinische Hochschule Hannover - Clinic for Pediatric Pneumology, Allergology and Neonatology, CF-Centre
Hanover, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Mukoviszidose-Zentrum am Universitätsklinikum Jena
Jena, Germany
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.